Hainan GeneralSanyang Pharmaceutical Co.,Ltd   Report issue

For profit Phase 1
Founded: Haikou China (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2015
NCT02467569
First Marketed Drug
2019
pregabalin (lyrica)
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

HAINAN

Active Ingredients

Marketed Drugs (2)

bivalirudin (angiomax) (2019)

pregabalin (lyrica) (2019)

Drugs in Phase 1 Trials (1)

hemay020 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1